My ePortfolio Register   

Results of the BELLE-3 study of buparlisib for advanced breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.12.16
Views: 784
Rating:

Dr Ruth O'Regan - University of Wisconsin-Madison, Madison, USA

Dr O'Regan speaks with ecancertv at SABCS 2016 about the outcomes of the phase III BELLE-3 trial, in which post-menopausal women with advanced or metastatic HR positive breast cancer who had disease progression during or after mTOR inhibitor therapy were treated with buparlisib and fulvestrant.

While the combination improved progression free survival at 6 months, as gauged by PIK3CA status, she notes the dose reductions and adverse events among a small number of patients in the trial, including incidences of depression and suicidal ideation.

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence